Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.

Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA.

J Thorac Oncol. 2011 Jun;6(6):1128-31. doi: 10.1097/JTO.0b013e3182161508.

2.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
3.

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Riely GJ.

J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S146-9. doi: 10.1097/JTO.0b013e318174e96e. Review.

4.

Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.

Takeuchi S, Yano S.

Respir Investig. 2014 Nov;52(6):348-56. doi: 10.1016/j.resinv.2014.10.002. Epub 2014 Oct 31. Review.

PMID:
25453378
5.

Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.

Köhler J, Schuler M.

Onkologie. 2013;36(9):510-8. doi: 10.1159/000354627. Epub 2013 Aug 19. Review.

6.

Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients.

Piperdi B, Perez-Soler R.

Drugs. 2012 Jun 19;72 Suppl 1:11-9. doi: 10.2165/1163018-S0-000000000-00000. Review.

7.

Biological and clinical implications of EGFR mutations in lung cancer.

Mitsudomi T, Kosaka T, Yatabe Y.

Int J Clin Oncol. 2006 Jun;11(3):190-8. Review.

PMID:
16850125
8.

Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.

Fukui T, Mitsudomi T.

Gen Thorac Cardiovasc Surg. 2008 Mar;56(3):97-103. doi: 10.1007/s11748-007-0193-8. Epub 2008 Mar 14. Review.

PMID:
18340507
9.

EGFR tyrosine kinase inhibitors: difference in efficacy and resistance.

Robinson KW, Sandler AB.

Curr Oncol Rep. 2013 Aug;15(4):396-404. doi: 10.1007/s11912-013-0323-7. Review.

PMID:
23674236
10.

Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.

Mok TS, D'arcangelo M, Califano R.

Drugs. 2012 Jun 19;72 Suppl 1:3-10. doi: 10.2165/1163014-S0-000000000-00000. Review.

PMID:
22712792
11.

Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.

Tong CWS, Wu WKK, Loong HHF, Cho WCS, To KKW.

Cancer Lett. 2017 Oct 1;405:100-110. doi: 10.1016/j.canlet.2017.07.023. Epub 2017 Jul 31. Review.

PMID:
28774798
12.

[Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report].

Durand M, Logerot S, Fonrose X, Schir E.

Therapie. 2014 Mar-Apr;69(2):163-8. doi: 10.2515/therapie/2014017. Epub 2014 Jun 12. Review. French.

PMID:
24926635
14.
15.

The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients.

Kruser TJ, Traynor AM, Wheeler DL.

Expert Opin Investig Drugs. 2011 Feb;20(2):305-7. doi: 10.1517/13543784.2011.550873. Epub 2011 Jan 5. Review.

16.

EGFR inhibition in NSCLC: New findings…. and opened questions?

Passiglia F, Listì A, Castiglia M, Perez A, Rizzo S, Bazan V, Russo A.

Crit Rev Oncol Hematol. 2017 Apr;112:126-135. doi: 10.1016/j.critrevonc.2017.02.009. Epub 2017 Feb 16. Review.

PMID:
28325254
17.

The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.

Gui T, Shen K.

Cancer Epidemiol. 2012 Oct;36(5):490-6. doi: 10.1016/j.canep.2012.06.005. Epub 2012 Jul 20. Review.

PMID:
22818908
18.

Advances on EGFR mutation for lung cancer.

Metro G, Crinò L.

Transl Lung Cancer Res. 2012 Mar;1(1):5-13. doi: 10.3978/j.issn.2218-6751.2011.12.01. Review.

19.

Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.

Waller LL, Miller AA, Petty WJ.

Lung Cancer. 2010 Jan;67(1):12-6. doi: 10.1016/j.lungcan.2009.08.014. Review.

PMID:
19762110
20.

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

Dutta PR, Maity A.

Cancer Lett. 2007 Sep 8;254(2):165-77. Epub 2007 Mar 23. Review.

Supplemental Content

Support Center